Feldman has disclosed he received grant/research support from Encysive Pharmaceuticals; has served as a consultant to United Therapeutics, Encysive, CoTherix, and Actelion; and served on the speakers' bureau of Encysive, Actelion, United Therapeutics, Myogen
, and Pfizer.
is a biopharmaceutical company engaged in therapeutics for cardiovascular disorders.
This year's 'Company of the Year' winner will be announced at the Awards Celebration and join a select group of companies that over the years has included Roche Colorado (2003), Pharmion (2004), Baxa Corporation (2005), Myogen
(2006), Allosource (2007), CaridianBCT (2008), Accera (2009), Amgen Colorado (2010) and LABS Inc.
According to the company, Dr Bristow was the principal founder of Myogen
biopharmaceutical company and Miragen Therapeutics.
She currently serves on the board of directors of VasoGenix Pharmaceuticals Inc and Chroma Therapeutics, and has previous board experience with Marion Merrell Dow, NexStar Pharmaceuticals, Cell Pathways, Schein, Pharmion, PRA International, Perrigo, Renovis, Myogen
, Zosano Pharma, Novacea, Health Shares, Zymogenetics, and Atani.
Weber disclosed that he is a consultant to Myogen
In January 2004, Myogen
initiated two pivotal Phase 3 clinical trials, ARIES-1 and ARIES-2, evaluating the safety and efficacy of ambrisentan in patients with PAH.
Then in October, after five consecutive quarters without a single traditional IPO (Neurochem began trading on Nasdaq in September but it was already listed on the Toronto exchange), Acusphere (ACUS), Advancis (AVNC), Myogen
(MYOG), CancerVax (CNVX) and Genitope (GTOP) made their debut on Nasdaq.
is a biopharmaceutical company focusing on the discovery, development and commercialization of small molecule therapeutics for treating cardiovascular disorders.
Gates Center for Regenerative Medicine and Stem Cell Biology and current Director and former Chair of the Children's Hospital Colorado Board of Directors; William Freytag, PhD, former Chairman and CEO of Myogen
Most recently Turner was chief financial officer for biopharmaceutical company Myogen
Inc until it was acquired by Gilead Sciences in 2006.
Bristow of the University of Colorado Health Sciences Center, Denver, designed the trial and is the founder and chief medical officer of Myogen